Rhythm Pharmaceuticals, Inc.

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. 

Rhythm is advancing a broad clinical development program across rare genetic diseases of obesity, including Bardet-Biedl syndrome (BBS), for the treatment of hunger and obesity due to genetic deficiencies associated with the MC4R pathway. In addition, Rhythm has created and is leveraging the largest known obesity DNA database of ~45,000 sequencing samples with the goal of improving the understanding, diagnosis, and care of patients with severe obesity due to certain genetic deficiencies. Rhythm’s Uncovering Rare Obesity® is a no-charge, comprehensive genetic testing program for rare genetic diseases of obesity.

For healthcare professionals, visit www.RareObesity.com to learn more about genetic obesity and its root cause. For resources on genetic testing, visit www.UncoveringRareObesity.com.

For patients and caregivers, visit www.LEADforRareObesity.com for more information. 

Contact Us:
For U.S.-based medical inquiries, please email medinfo@rhythmtx.com
For patient and caregiver inquiries, please email PatientAdvocacy@rhythmtx.com